Analysed APTEVO THERAPEUTICS INC (APVO:NASDAQ) News Sources
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
10-03-2026
yahoo.com
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
06-05-2026
yahoo.com
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
13-05-2026
yahoo.com
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
27-05-2026
yahoo.com
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
28-05-2026
yahoo.com
APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement
16-06-2026
yahoo.com
What is the current price of APTEVO THERAPEUTICS INC (APVO:NASDAQ)?
The current price of APTEVO THERAPEUTICS INC (APVO:NASDAQ) is $3.94.
APTEVO THERAPEUTICS INC (APVO:NASDAQ) absolute price change since previous trading day?
The absolute price change of APTEVO THERAPEUTICS INC (APVO:NASDAQ) since the previous trading day is $0.
APTEVO THERAPEUTICS INC (APVO:NASDAQ) percentage price change since previous trading day?
The percentage price change of APTEVO THERAPEUTICS INC (APVO:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for APTEVO THERAPEUTICS INC (APVO:NASDAQ)?
The most recent average sentiment score for APTEVO THERAPEUTICS INC (APVO:NASDAQ) is 87 out of 100.
What is the most recent average sentiment for APTEVO THERAPEUTICS INC (APVO:NASDAQ)?
The most recent sentiment for APTEVO THERAPEUTICS INC (APVO:NASDAQ) is .
SEC-8K** Filing Available For APTEVO THERAPEUTICS INC (APVO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.